Table 1.
Variable | Value |
---|---|
Subjects | |
N | 42 |
age (years) | 56.8±15.5 |
sex (male/female) | 25/17 |
weight (kg) | 95.1±26.8 |
AKI | 36/42 |
24-hour urine output (ml) | 38 (157) |
CCF score (n=36) | 7.9±2.8 |
survival (%) | 50.0 |
center (CCF/UAB) | 19/23 |
Treatment | |
CRRT mode (CVVHD/CVVHDF) | 19/23 |
CRRT dose (ml/kg per hour) | 25.7 (15.8) |
CRRT machine (Prismaflex/NxStage) | 34/8 |
piperacillin dose (2 g/3 g) | 19/23 |
piperacillin dosing interval (6 h/8 h/12 h) | 23/16/3 |
cumulative 24-hour piperacillin dose (g) | 8.6±1.5 |
Data are presented as mean ± SD or median (intraquartile range). CCF, Cleveland Clinic, Cleveland, Ohio; UAB, University of Alabama, Birmingham, Alabama; CRRT, continuous renal replacement therapy; CVVHD, continuous venovenous hemodialysis; CVVHDF, continuous venovenous hemodiafiltration.